s'authentifier
version française rss feed
Fiche concise
In vivo protective role of human group IIA phospholipase A2 against experimental anthrax
Piris-Gimenez A., Paya M., Lambeau G., Chignard M., Mock M., Touqui L., Goossens P. L.
Journal of immunology (Baltimore, Md. : 1950) 175 (2005) 6786-6791 - http://hal.archives-ouvertes.fr/hal-00083712
Sciences du Vivant/Microbiologie et Parasitologie
Sciences du Vivant/Immunologie
(16272335)
In vivo protective role of human group IIA phospholipase A2 against experimental anthrax
Alejandro Piris-Gimenez1, Miguel Paya2, Gérard Lambeau3, Michel Chignard2, Michèle Mock1, Lhousseine Touqui () 2, Pierre L. Goossens () 1
1 :  Toxines et Pathogénie Bactérienne
CNRS : URA2172 – Institut Pasteur de Paris
25-28 rue du Docteur Roux, F-75724 Paris Cedex 15
France
2 :  Défense Innée et Inflammation Pulmonaire
INSERM : E336 – Institut Pasteur de Paris
25, Rue du Docteur Roux 75724 PARIS CEDEX 15
France
3 :  IPMC - Institut de pharmacologie moléculaire et cellulaire
http://www.ipmc.cnrs.fr/
CNRS : UMR6097 – Université Nice Sophia Antipolis [UNS]
CNRS-IPMC 660 Route des lucioles 06560 VALBONNE
France
Anthrax is an acute disease caused by Bacillus anthracis. Some animal species are relatively resistant to anthrax infection. This trait has been correlated to the extent of the local inflammatory reaction, suggesting innate immunity to be the first line of defense against B. anthracis infection in nonimmunized hosts. Group IIA secreted phospholipase A2 (sPLA2-IIA) is produced in particular by macrophages and possesses potent antibacterial activity especially against Gram-positive bacteria. We have previously shown in vitro that sPLA 2-IIA kills both germinated B. anthracis spores and encapsulated bacilli. Here we show that sPLA2-IIA plays in vivo a protective role against experimental anthrax. Transgenic mice expressing human sPLA2-IIA are resistant to B. anthracis infection. In addition, in vivo administration of recombinant human sPLA2-IIA protects mice against B. anthracis infection. The protective effect was observed both with a highly virulent encapsulated nontoxinogenic strain and a wild-type encapsulated toxinogenic strain, showing that toxemia did not hinder the sPLA2-IIA-afforded protection. sPLA2-IIA, a natural component of the immune system, may thus be considered a novel therapeutic agent to be used in adjunct with current therapy for treating anthrax. Its anthracidal activity would be effective even against strains resistant to multiple antibiotics.
Anglais

Articles dans des revues avec comité de lecture
Journal of immunology (Baltimore, Md. : 1950)
internationale
2005
175
6786-6791